April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional GI/disorder of gut-brain interaction professionals and organizations who are uniting in

The American Journal of Gastroenterology has published the American College of Gastroenterology’s  newly updated guidelines for the management of irritable bowel syndrome (IBS) in its December 2020 issue. Seven named authors from the fields of gastroenterology  and gastrointestinal health psychology, represent five United States universities or academic medical centers that are leaders in IBS research.

Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research, medical care and support systems since then. Now in 2020, IFFGD

This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved for adults. It has not been approved for youth under the

The U.S Food and Drug Administration (FDA) has approved marketing of the IB-Stim device, for use in adolescents, ages 11-18, with functional gastrointestinal pain related to irritable bowel syndrome (IBS). IB-Stim, developed by Innovative Health Solutions in Indiana, is a small nerve stimulator device powered by a battery and intended to be worn behind the

The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology,  health psychology and primary care, represent six Canadian universities with one author currently unaffiliated. These are McMaster University, the University

At the end of March 2019, the U.S Food and Drug Administration (FDA) approved the reintroduction of tegaserod (brand name Zelnorm), an oral medication for irritable bowel syndrome with constipation (IBS-C) to the U.S., only for women without risk factors for or history of cardiovascular conditions. Tegaserod, a selective serotonin type 4 receptor partial agonist

According to news releases, the Canadian branch of Lupin Pharmaceuticals, the distributor of Rifaximin, recently announced that Health Canada, the Canadian drug regulatory agency, has approved its use for irritable bowel syndrome with diarrhea (IBS-D). Rifaximin, which is manufactured by Salix Pharmaceuticals in the United States, is known by the brand name Xifaxan in the

The International Foundation for Functional Gastrointestinal Disorders (IFFGD) is an established, reputable U.S. based 501c3 not-for-profit organization/charity focused on irritable bowel syndrome (IBS) and related functional gastrointestinal disorders, also known as disorders of gut-brain interaction. IFFGD was founded in 1991 by an FGID-affected family and continues to have people with FGIDs or family members/supporters among

In April 2018, the journal Gastroenterology  reported that an international collaboration of researchers headed by the Karolinska Institutet in Sweden, has identified several DNA variants on Chromosome 9 that may be associated with higher risk of IBS in women, particularly IBS with constipation. This possible correlation was not found in men. The identified chromosomal regions